Utilization Patterns of Pulmicort in Real Life Practice

AstraZeneca

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT00660569

NIS-RES-PUL-2007/1

Details and patient eligibility

About

The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.

Enrollment: 260 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
• Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion criteria

• Disability that, from investigator point of view, prevent from complying the follow up schedule
• To have participated in any clinical study in the past 6 months

Trial design

260 participants in 1 patient group

1

Description:

Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA